Dysphonia after Bevacizumab Rechallenge: A Case Report
Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2015-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/441122 |
| _version_ | 1829507602303680512 |
|---|---|
| author | Corey A. Carter Scott Z. Caroen Arnold L. Oronsky Bryan T. Oronsky |
| author_facet | Corey A. Carter Scott Z. Caroen Arnold L. Oronsky Bryan T. Oronsky |
| author_sort | Corey A. Carter |
| collection | DOAJ |
| description | Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the normal (nontumor) vasculature. Dysphonia or voice changes have been anecdotally reported in patients that have been exposed to antiangiogenics. In this case report, we present an occurrence of severe dysphonia in a 60-year-old male with metastatic colorectal cancer after reintroduction of irinotecan and bevacizumab. To our knowledge, this is the first case of dysphonia associated with bevacizumab rechallenge. |
| first_indexed | 2024-12-16T11:10:48Z |
| format | Article |
| id | doaj.art-485fa0c558b54843a9ce8b90121b19da |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-16T11:10:48Z |
| publishDate | 2015-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-485fa0c558b54843a9ce8b90121b19da2022-12-21T22:33:44ZengKarger PublishersCase Reports in Oncology1662-65752015-10-018342342510.1159/000441122441122Dysphonia after Bevacizumab Rechallenge: A Case ReportCorey A. CarterScott Z. CaroenArnold L. OronskyBryan T. OronskyInhibition of vascular endothelial growth factor (VEGF) signaling, an initiator of tumor angiogenesis, inhibits tumor growth and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as an adjunct to standard chemotherapy like irinotecan in advanced colorectal cancer, also affects the normal (nontumor) vasculature. Dysphonia or voice changes have been anecdotally reported in patients that have been exposed to antiangiogenics. In this case report, we present an occurrence of severe dysphonia in a 60-year-old male with metastatic colorectal cancer after reintroduction of irinotecan and bevacizumab. To our knowledge, this is the first case of dysphonia associated with bevacizumab rechallenge.http://www.karger.com/Article/FullText/441122OncologyBevacizumabDysphoniaAntiangiogenics |
| spellingShingle | Corey A. Carter Scott Z. Caroen Arnold L. Oronsky Bryan T. Oronsky Dysphonia after Bevacizumab Rechallenge: A Case Report Case Reports in Oncology Oncology Bevacizumab Dysphonia Antiangiogenics |
| title | Dysphonia after Bevacizumab Rechallenge: A Case Report |
| title_full | Dysphonia after Bevacizumab Rechallenge: A Case Report |
| title_fullStr | Dysphonia after Bevacizumab Rechallenge: A Case Report |
| title_full_unstemmed | Dysphonia after Bevacizumab Rechallenge: A Case Report |
| title_short | Dysphonia after Bevacizumab Rechallenge: A Case Report |
| title_sort | dysphonia after bevacizumab rechallenge a case report |
| topic | Oncology Bevacizumab Dysphonia Antiangiogenics |
| url | http://www.karger.com/Article/FullText/441122 |
| work_keys_str_mv | AT coreyacarter dysphoniaafterbevacizumabrechallengeacasereport AT scottzcaroen dysphoniaafterbevacizumabrechallengeacasereport AT arnoldloronsky dysphoniaafterbevacizumabrechallengeacasereport AT bryantoronsky dysphoniaafterbevacizumabrechallengeacasereport |